Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study to Evaluate 18F Florbetapir Binding to Cardiac Amyloid in Patients Undergoing Chemotherapy

Trial Profile

A Pilot Study to Evaluate 18F Florbetapir Binding to Cardiac Amyloid in Patients Undergoing Chemotherapy

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2018

At a glance

  • Drugs Florbetapir F 18 (Primary)
  • Indications Amyloidosis
  • Focus Diagnostic use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 15 Aug 2018 Planned End Date changed from 1 Apr 2019 to 1 Jan 2021.
    • 15 Aug 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Jan 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top